Divis Laboratories Ltd - 532488 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0440 Name of the Signatory :- M Satish ChoudhuryDesignation :- Company Secretary and Compliance Officer Divis Laboratories Ltd - 532488 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we herewith submit certificate for the quarter ended March 31, 2021 received from M/s. KFin Technologies Private Limited, Registrar & Share Transfer Agent of the Company. Divis Laboratories Ltd - 532488 - Compliance Certificate For Half Year Ended March 31, 2021
Pursuant to Regulation7(3) of the SEBI (LODR) Regulations, 2015, we enclose herewith Compliance Certificate from the Company and the Registrar and Share Transfer Agent for half year ended March 31, 2021. Divis Laboratories Ltd - 532488 - Shareholding for the Period Ended March 31, 2021
Divis Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here DIVI'S LABORATORIES LTD. - 532488 - Closure of Trading Window
Pursuant to the Company's Code of Conduct for Prevention of Insider Trading (the Code), we hereby inform that the Trading Window for dealing in securities of the Company will remain closed for all Designated Persons and their Immediate Relatives, as well as Insiders covered under the Code, from 01 April, 2021 till 48 hours after the declaration of Audited Financial Results of the Company for the fourth quarter and year ending on 31 March, 2021. The date of Board Meeting for declaration of the financial results of the Company for the fourth quarter and year ending on 31 March, 2021 will be intimated in due course. Divis Laboratories Ltd - 532488 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Request for issue of Duplicate Share Certificate
Buy Divis Laboratories: target of Rs 4500: Sharekhan
Sharekhan is bullish on Divis Laboratories has recommended buy rating on the stock with a target price of Rs 4500 in its research report dated March 23, 2021.
Gladiator Stocks - Divis Laboratories: ICICI Direct
According to ICICI Direct, Buy Divis Laboratories in the range of Rs 3280.003325.00 for target price of Rs 3740.00 with a stop loss of Rs 3110.00. Time Frame: Six months.
Earnings Call for Q3FY21 of Divi's Laboratories
Conference Call with Divi's Laboratories Management and Analysts on Q3FY21 Performance and Outlook. Listen to the full earnings transcript.